These results highlight a mechanistic link between ceramide and CTSB in the regulation of GCase activity and suggest that targeting lysosomal ceramide or CTSB may be an effective therapeutic strategy to activate Sap C/GCase axis in PD and related disorders. This evidence concerns the gene CTSB and Parkinson disease.